Skip to content

Phase-IIa randomized, double-blind, sham-controlled, parallel group trial on anodal tDCS over the left and right tempo-parietal junction in Autism Spectrum Disorder

Phase-IIa randomized, double-blind, sham-controlled, parallel group trial on anodal tDCS over the left and right tempo-parietal junction in Autism Spectrum Disorder - StimAT

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
DRKS
Registry ID
DRKS00014732
Enrollment
100
Registered
2018-08-15
Start date
2018-08-15
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DSM-5 299.0 Autism Spectrum Disorder F84.0 F84.1 F84.5

Interventions

Group 1: Children and adolescents with ASD receiving real electric stimulation (tDCS, 2mA current for 20 minutes) concurrent with computer based cognitive training over two weeks of five consecutive d

Sponsors

Goethe University Frankfurt
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 17 Years

Inclusion criteria

Inclusion criteria: •Expert clinical ASD diagnosis according to DSM-5 supported by ADI-R and ADOS, including all Autism Spectrum Disorders (299.00) •Age = 10 to <18 years old at randomization •participant and their parents are able and willing to give written informed assent/consent

Exclusion criteria

Exclusion criteria: •IQ=70 o Developmental coordination disorder o Major Depressive Disorder: Mild Depressive Episode o Dysthymia o All Anxiety Disorders o All Elimination Disorders o Gender Dysphoria o Oppositional Defiant Disorder o ASD-related sleeping problems o ASD-related eating problems •Dermatological disease of the scalp or chronic skin damage •Any electrically, mechanically or magnetically activated implant (for example, brain implant, pacemakers, cardiac implants, vascular clips) •Heart disease •Current pregnancy or hormonal contraception •History of smoking within last five years •Concurrent psychopharmacological treatment that has an influence on the central nervous system •Concurrent neurofeedback or stimulation therapy •Participation in other clinical trials

Design outcomes

Primary

MeasureTime frame
-Change in the parent-rated Social Responsiveness Scale questionnaire (SRS-16 item short version,) between pre- and post-intervention

Secondary

MeasureTime frame
-Change in parent rated social responsiveness questionnaire (SRS-16 item short version) between pre-intervention and at four weeks follow-up -Change in repetitive behavior (RBS-r), communication (CCC-2), additional psychopathology (CBCL, ABC), health-related quality of life (KIDSCREEN27, child and parent) and social cognition based on questionnaires, imitation ability based on behavioral observation (Imitation of non-meaningful gestures) between pre- and post-intervention and follow-up of four weeks -Change in neuropsychological (CANTAB), neurophysiological tasks and resting-state fMRI tasks between pre- and post-intervention and follow-up of four weeks

Countries

France, Germany, Portugal

Contacts

Public ContactChristina Luckhardt

Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy & Autism Research and Intervention Center of Excellence, University Hospital Frankfurt, Goethe University

KJP_stiped@kgu.deDE 069630184057

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 23, 2026